

# Marco Bianchi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7702202/marco-bianchi-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114  
papers

4,703  
citations

36  
h-index

64  
g-index

118  
ext. papers

5,636  
ext. citations

4.9  
avg, IF

4.74  
L-index

#	Paper	IF	Citations
114	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. <i>European Urology Focus</i> , <b>2021</b> , 7, 1092-1099	5.1	1
113	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 48-53	9.7	15
112	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 235.e15-235.e21	2.8	3
111	Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution. <i>Minerva Urology and Nephrology</i> , <b>2021</b> , 73, 481-488	2.3	2
110	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , <b>2020</b> , 77, 701-710	10.2	66
109	Association of an immune gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 533-533	2.2	
108	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. <i>European Urology</i> , <b>2020</b> , 77, 439-446	10.2	119
107	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , <b>2020</b> , 77, 636-643	10.2	48
106	Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. <i>European Urology Oncology</i> , <b>2019</b> , 2, 456-463	6.7	8
105	PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4595-TPS4595	2.2	0
104	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3353-3360	2.2	265
103	Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. <i>Urologia</i> , <b>2017</b> , 84, 9-19	1.2	20
102	Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. <i>European Urology</i> , <b>2016</b> , 69, 193-6	10.2	25
101	Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction?. <i>Journal of Sexual Medicine</i> , <b>2016</b> , 13, 669-78	1.1	9
100	Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 118, 79-84	5.3	42
99	The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status. <i>European Urology Focus</i> , <b>2016</b> , 2, 86-91	5.1	12
98	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 256.e7-256.e13	2.8	15

97	The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. <i>European Urology</i> , <b>2016</b> , 69, 1142-8	10.2	38
96	Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e245-50	3.3	4
95	Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 234.e13-9	2.8	13
94	Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. <i>World Journal of Urology</i> , <b>2015</b> , 33, 1419-28	4	16
93	A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , <b>2015</b> , 68, 750-3	10.2	28
92	Penile rehabilitation after radical prostatectomy: does it work?. <i>Translational Andrology and Urology</i> , <b>2015</b> , 4, 110-23	2.3	24
91	Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 29.e21-8	2.8	20
90	Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample. <i>World Journal of Urology</i> , <b>2014</b> , 32, 1511-21	4	11
89	A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 90, 49-57	7	3
88	Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 27.e7-13	2.8	22
87	A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 46.e1-7	2.8	18
86	Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, E148-58	1.2	22
85	Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, E75-80	1.2	4
84	Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data. <i>BJU International</i> , <b>2014</b> , 113, 36-42	5.6	27
83	Partial and radical nephrectomy provide comparable long-term cancer control for T1b renal cell carcinoma. <i>International Journal of Urology</i> , <b>2014</b> , 21, 122-8	2.3	23
82	Survival after nephroureterectomy for upper tract urothelial carcinoma: a population-based competing-risks analysis. <i>International Journal of Urology</i> , <b>2014</b> , 21, 249-56	2.3	17
81	Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis. <i>BJU International</i> , <b>2014</b> , 113, 733-40	5.6	21
80	Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score. <i>BJU International</i> , <b>2014</b> , 113, 399-407	5.6	18

79	Predicting survival of patients with node-positive prostate cancer following multimodal treatment. <i>European Urology</i> , <b>2014</b> , 65, 554-62	10.2	61
78	Trends in surgical management of T1 renal cell carcinoma. <i>Current Urology Reports</i> , <b>2014</b> , 15, 383	2.9	12
77	External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. <i>Prostate</i> , <b>2013</b> , 73, 211-8	4.2	45
76	Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged $\geq 5$ years with multiple comorbidities. <i>BJU International</i> , <b>2013</b> , 111, 67-73	5.6	46
75	Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery. <i>BJU International</i> , <b>2013</b> , 111, 717-22	5.6	73
74	Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time. <i>BJU International</i> , <b>2013</b> , 111, E283-9	5.6	26
73	Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. <i>European Urology</i> , <b>2013</b> , 63, 693-701	10.2	78
72	Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 109, 211-6	5.3	15
71	Robot-assisted versus open radical prostatectomy: the differential effect of regionalization, procedure volume and operative approach. <i>Journal of Urology</i> , <b>2013</b> , 189, 1289-94	2.5	73
70	Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 2096-102	3.1	15
69	A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 388-401	14.4	24
68	An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , <b>2013</b> , 5, 121-8	3.2	15
67	Reply to Georgios Papadopoulos, Georgios Stathouros and Konstantinos Doumas Letter to the editor Re: Maxine Sun, Marco Bianchi, Jens Hansen, et al. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. <i>Eur Urol</i> 2012;62:696-703. <i>European Urology</i> , <b>2013</b> , 63, e65-6	10.2	
66	The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer. <i>Journal of Urology</i> , <b>2013</b> , 189, 854-9	2.5	11
65	Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1497-503	2.8	11
64	Discharge patterns after radical prostatectomy in the United States of America. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1022-32	2.8	19
63	Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. <i>European Urology</i> , <b>2013</b> , 63, 998-1008	10.2	88
62	In-hospital mortality and failure to rescue after cytoreductive nephrectomy. <i>European Urology</i> , <b>2013</b> , 63, 1107-14	10.2	45

61	Nodal involvement at nephrectomy is associated with worse survival: a stage-for-stage and grade-for-grade analysis. <i>International Journal of Urology</i> , <b>2013</b> , 20, 372-80	2.3	16
60	Fuhrman grade [corrected] has no added value in prediction of mortality after partial or [corrected] radical nephrectomy for chromophobe renal cell carcinoma patients. <i>Modern Pathology</i> , <b>2013</b> , 26, 1144-9	9.8	8
59	An analysis of patients with T2 renal cell carcinoma (RCC) according to tumour size: a population-based analysis. <i>BJU International</i> , <b>2013</b> , 111, 1184-90	5.6	3
58	Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre. <i>BJU International</i> , <b>2013</b> , 111, 1222-30	5.6	28
57	A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy. <i>BJU International</i> , <b>2013</b> , 111, 905-13	5.6	13
56	Rates of open versus laparoscopic and partial versus radical nephrectomy for T1a renal cell carcinoma: a population-based evaluation. <i>International Journal of Urology</i> , <b>2013</b> , 20, 1064-71	2.3	32
55	Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance. <i>BJU International</i> , <b>2013</b> , 112, E234-42	5.6	1
54	Robot-assisted vs. laparoscopic partial nephrectomy: utilization rates and perioperative outcomes. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2013</b> , 39, 377-86	2	22
53	Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. <i>European Urology</i> , <b>2012</b> , 61, 480-7	10.2	425
52	Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. <i>European Urology</i> , <b>2012</b> , 61, 1132-8	10.2	95
51	A non-cancer-related survival benefit is associated with partial nephrectomy. <i>European Urology</i> , <b>2012</b> , 61, 725-31	10.2	95
50	Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series. <i>European Urology</i> , <b>2012</b> , 61, 715-21	10.2	52
49	Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. <i>European Urology</i> , <b>2012</b> , 61, 679-85	10.2	289
48	Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses. <i>European Urology</i> , <b>2012</b> , 62, 42-52	10.2	54
47	A review of integrated staging systems for renal cell carcinoma. <i>European Urology</i> , <b>2012</b> , 62, 303-14	10.2	63
46	Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated?. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 903-8	1.1	29
45	Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer?. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 2961-9	1.1	25
44	Extended pelvic lymph node dissection does not affect erectile function recovery in patients treated with bilateral nerve-sparing radical prostatectomy. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 2187-94	1.1	17

43	Open radical prostatectomy in the elderly: a case for concern?. <i>BJU International</i> , <b>2012</b> , 109, 1335-40	5.6	11
42	Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA. <i>BJU International</i> , <b>2012</b> , 109, 1807-12	5.6	26
41	Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort. <i>BJU International</i> , <b>2012</b> , 110, E21-7	5.6	22
40	Prospective randomized trial of barbed polyglyconate suture to facilitate vesico-urethral anastomosis during robot-assisted radical prostatectomy: time reduction and cost benefit. <i>BJU International</i> , <b>2012</b> , 109, 1526-32	5.6	51
39	Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis. <i>BJU International</i> , <b>2012</b> , 110, E183-90	5.6	14
38	Venous thromboembolism after radical prostatectomy: the effect of surgical caseload. <i>BJU International</i> , <b>2012</b> , 110, 828-33	5.6	13
37	Marital status: a gender-independent risk factor for poorer survival after radical cystectomy. <i>BJU International</i> , <b>2012</b> , 110, 1301-9	5.6	36
36	Treatment management of small renal masses in the 21st century: a paradigm shift. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 2380-7	3.1	74
35	Does partial nephrectomy at an academic institution result in better outcomes?. <i>World Journal of Urology</i> , <b>2012</b> , 30, 505-10	4	6
34	Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. <i>European Urology</i> , <b>2012</b> , 62, 696-703	10.2	110
33	Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. <i>European Urology</i> , <b>2012</b> , 62, 472-87	10.2	129
32	Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, 624-9	4	20
31	Hospital volume is a determinant of postoperative complications, blood transfusion and length of stay after radical or partial nephrectomy. <i>Journal of Urology</i> , <b>2012</b> , 187, 405-10	2.5	50
30	Discharge patterns after radical cystectomy: contemporary trends in the United States. <i>Journal of Urology</i> , <b>2012</b> , 187, 1206-9	2.5	2
29	Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. <i>Journal of Urology</i> , <b>2012</b> , 188, 73-83	2.5	35
28	Blood transfusions in radical prostatectomy: a contemporary population-based analysis. <i>Urology</i> , <b>2012</b> , 79, 332-8	1.6	16
27	Annual prostatectomy volume is related to rectal laceration rate after radical prostatectomy. <i>Urology</i> , <b>2012</b> , 79, 796-803	1.6	10
26	Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy. <i>Urology</i> , <b>2012</b> , 80, 347-53	1.6	43

25	Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 1503-11	7.5	39
24	National Comprehensive Cancer Network practice guidelines 2011: Need for more accurate recommendations for pelvic lymph node dissection in prostate cancer. <i>Journal of Urology</i> , <b>2012</b> , 188, 423-8	2.5	19
23	National trends and disparities in the use of minimally invasive adult pyeloplasty. <i>Journal of Urology</i> , <b>2012</b> , 188, 913-8	2.5	31
22	Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum. <i>Prostate</i> , <b>2012</b> , 72, 186-92	4.2	58
21	Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. <i>Prostate</i> , <b>2012</b> , 72, 499-506	4.2	10
20	There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. implications for focal therapies. <i>Prostate</i> , <b>2012</b> , 72, 925-30	4.2	11
19	Morbidity and mortality of radical prostatectomy differs by insurance status. <i>Cancer</i> , <b>2012</b> , 118, 1803-106.4		34
18	Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States. <i>Cancer</i> , <b>2012</b> , 118, 1894-900	6.4	22
17	Disparities in access to care at high-volume institutions for uro-oncologic procedures. <i>Cancer</i> , <b>2012</b> , 118, 4421-6	6.4	52
16	Leapfrog volume thresholds and perioperative complications after radical prostatectomy. <i>Cancer</i> , <b>2012</b> , 118, 4991-8	6.4	15
15	The effect of insurance status on outcomes after partial nephrectomy. <i>International Urology and Nephrology</i> , <b>2012</b> , 44, 343-51	2.3	9
14	The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy. <i>International Urology and Nephrology</i> , <b>2012</b> , 44, 799-806	2.3	7
13	Optimizing postoperative sexual function after radical prostatectomy. <i>Therapeutic Advances in Urology</i> , <b>2012</b> , 4, 347-65	3.2	12
12	Proof of efficacy is not enough: contemporary management of patients with metastatic renal cell carcinoma with targeted therapy. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3901; author reply 3902	2.2	3
11	Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study. <i>Canadian Urological Association Journal</i> , <b>2012</b> , 6, 245-50	1.2	15
10	Radical prostatectomy at academic versus nonacademic institutions: a population based analysis. <i>Journal of Urology</i> , <b>2011</b> , 186, 1849-54	2.5	32
9	What is the definition of a satisfactory erectile function after bilateral nerve sparing radical prostatectomy?. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 1210-7	1.1	32
8	Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. <i>European Urology</i> , <b>2011</b> , 59, 832-40	10.2	141

7	A population-based analysis of temporal perioperative complication rates after minimally invasive radical prostatectomy. <i>European Urology</i> , <b>2011</b> , 60, 564-71	10.2	17
6	A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis. <i>European Urology</i> , <b>2011</b> , 60, 1152-9	10.2	28
5	Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 2521-31	1.1	85
4	Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant radiotherapy. <i>European Urology</i> , <b>2009</b> , 55, 211-7	10.2	213
3	Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. <i>European Urology</i> , <b>2009</b> , 55, 1003-11	10.2	138
2	Prediction of sexual function after radical prostatectomy. <i>Cancer</i> , <b>2009</b> , 115, 3150-9	6.4	31
1	Benign Prostatic Hyperplasia and Its Aetiologies. <i>European Urology Supplements</i> , <b>2009</b> , 8, 865-871	0.9	75